BioGX: Difference between revisions

From Bhamwiki
Jump to navigation Jump to search
No edit summary
Line 10: Line 10:
* Patchen, Tyler (October 27, 2020) "Birmingham company secures FDA emergency use authorization for Covid-19 test." {{BBJ}}
* Patchen, Tyler (October 27, 2020) "Birmingham company secures FDA emergency use authorization for Covid-19 test." {{BBJ}}
* Patchen, Tyler (January 26, 2021) "BioGX to move to facility on Valleydale Road." {{BBJ}}
* Patchen, Tyler (January 26, 2021) "BioGX to move to facility on Valleydale Road." {{BBJ}}
* Thornton, William (February 4, 2021) "BioGX moving to Shelby County, to hire 30." {{BN}}


==External links==
==External links==

Revision as of 14:14, 5 February 2021

BioGX is a molecular diagnostics company headquartered at 2450 Valleydale Road. The company also operates a second manufacturing and distribution center, BioGX BV, in Amsterdam, the Netherlands.

BioGX was founded in 2007 by Michael Vickery and was located in Birmingham's Innovation Depot until purchasing its present 30,000 square-foot building in 2021. Shazi Iqbal has served as CEO since 2011. Both are veterans of the Sunnyvale, California-based Cepheid Inc.

BioGX partnered with Becton Dickinson & Co. of New Jersey to develop a rapid COVID-19 RNA test for its "BD Max" diagnostic platform. The test was granted an emergency use authorization from the U.S. Food and Drug Administration in April 2020. It's "XFree" test process was given the same type of approval in October.

References

External links